Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep 1;27(9):712-713.
doi: 10.5588/ijtld.23.0220.

Bedaquiline-based all-oral regimen for macrolide-resistant Mycobacterium abscessus pulmonary disease

N Riccardi  1 , S Occhineri  1 , T Matucci  1 , G Marchetti  1 , L Rindi  2 , G Tiseo  3 , D M Cirillo  4 , M Falcone  3
Affiliations
Comment

Bedaquiline-based all-oral regimen for macrolide-resistant Mycobacterium abscessus pulmonary disease

N Riccardi et al. Int J Tuberc Lung Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none declared.

Figures

Figure
Figure
Radiological comparison of a patient with Mycobacterium abscessus before and after treatment with bedaquiline-based all-oral regimen. Panels A, B and C show diffuse cystic bronchiectasis, and a cavitated nodularity in the middle lobe and in the right lower lobe at baseline. In panels D, E and F, numerical and dimensional reduction of some of the most appreciable cavitated consolidations to the right is documented after 7 months. The apical segment of the right lower lobe shows no signs of cavitation.
See this image and copyright information in PMC

Comment on

References

    1. Chung C, et al. Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB. Int J Tuberc Lung Dis. 2023;27(2):151–153. - PubMed
    1. Daley CL, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535. Jul 7. - PMC - PubMed
    1. Reuter A, et al. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis. 2017;21(11):1114–1126. - PubMed
    1. Riccardi N, et al. Bedaquiline: a new hope for shorter and better anti-tuberculosis regimens. Recent Pat Antiinfect Drug Discov. 2018;13(1):3–11. - PubMed
    1. Chan WY, et al. A child with acute myeloid leukemia complicated by calcaneal osteomyelitis due to Mycobacterium abscessus infection after induction chemotherapy successfully salvaged with bedaquiline and clofazimine. Int J Infect Dis. 2021;103:9–12. - PubMed

LinkOut - more resources